Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 244

1.

Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review.

Curiel RV, Guzman NJ.

Semin Arthritis Rheum. 2012 Oct;42(2):166-78. doi: 10.1016/j.semarthrit.2012.03.013. Review.

PMID:
22560299
2.

Management of gouty arthritis in patients with chronic kidney disease.

Abdellatif AA, Elkhalili N.

Am J Ther. 2014 Nov-Dec;21(6):523-34. doi: 10.1097/MJT.0b013e318250f83d. Review.

PMID:
22960848
3.

Management of acute and chronic gouty arthritis: present state-of-the-art.

Schlesinger N.

Drugs. 2004;64(21):2399-416. Review.

PMID:
15481999
4.

Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.

Ernst ME, Fravel MA.

Clin Ther. 2009 Nov;31(11):2503-18. doi: 10.1016/j.clinthera.2009.11.033. Review.

PMID:
20109996
5.

Pegloticase for treatment of tophaceous polyarticular gout.

Seifried RM, Roberts J.

Hawaii J Med Public Health. 2013 Jul;72(7):220-3.

6.

Febuxostat: drug review and update.

Grewal HK, Martinez JR, Espinoza LR.

Expert Opin Drug Metab Toxicol. 2014 May;10(5):747-58. doi: 10.1517/17425255.2014.904285. Review.

PMID:
24684266
7.

[Gout and other crystal-induced arthritides].

Manger B.

Dtsch Med Wochenschr. 2012 Aug;137(31-32):1579-81. doi: 10.1055/s-0032-1305108. Review. German. No abstract available.

PMID:
22786675
8.

New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond.

Schlesinger N.

Curr Rheumatol Rep. 2010 Apr;12(2):130-4. doi: 10.1007/s11926-010-0093-2. Review.

PMID:
20425022
9.

[Gout and hyperuricaemia--should both be treated?].

Uhlig T.

Tidsskr Nor Laegeforen. 2003 Oct 23;123(20):2878-80. Review. Norwegian.

PMID:
14600714
10.

Pegloticase for treating refractory chronic gout.

George RL Jr, Sundy JS.

Drugs Today (Barc). 2012 Jul;48(7):441-9. doi: 10.1358/dot.2012.48.7.1813475. Review.

PMID:
22844655
11.

Safety and efficacy of allopurinol in chronic kidney disease.

Thurston MM, Phillips BB, Bourg CA.

Ann Pharmacother. 2013 Nov;47(11):1507-16. doi: 10.1177/1060028013504740. Review.

PMID:
24259601
12.

Advances in the management of gout and hyperuricaemia.

Hoskison TK, Wortmann RL.

Scand J Rheumatol. 2006 Jul-Aug;35(4):251-60. Review.

PMID:
16882587
13.

Pharmacokinetics considerations for gout treatments.

Richette P, Frazier A, Bardin T.

Expert Opin Drug Metab Toxicol. 2014 Jul;10(7):949-57. doi: 10.1517/17425255.2014.915027. Review.

PMID:
24809930
14.

Gouty arthritis. A primer on late-onset gout.

Ene-Stroescu D, Gorbien MJ.

Geriatrics. 2005 Jul;60(7):24-31. Review.

PMID:
16026179
15.

[Gout: an overview of available urate lowering therapies].

Richette P.

Ann Pharm Fr. 2012 May;70(3):133-8. doi: 10.1016/j.pharma.2012.02.003. Review. French.

PMID:
22655581
16.

Evaluation and treatment of gout as a chronic disease.

Perez-Ruiz F, Herrero-Beites AM.

Adv Ther. 2012 Nov;29(11):935-46. doi: 10.1007/s12325-012-0059-z. Review. Erratum in: Adv Ther. 2012 Dec;29(12):1067. Dosage error in article text.

PMID:
23104464
17.

Control of flares and relief of urate burden with canakinumab and targeted urate-lowering therapy in tophaceous gouty arthritis.

Fanouriakis A, Karantanas A, Fragouli E, Repa A, Sidiropoulos P.

Rheumatology (Oxford). 2014 Apr;53(4):764-6. doi: 10.1093/rheumatology/ket327. No abstract available.

PMID:
24185764
18.

Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy.

Schlesinger N.

Semin Arthritis Rheum. 2012 Oct;42(2):155-65. doi: 10.1016/j.semarthrit.2012.03.010. Review.

PMID:
22542277
19.
20.

Case 9: initiation of urate-lowering therapy for advanced gout complicated by chronic renal insufficiency.

Edwards NL.

Am J Med. 2006 Nov;119(11 Suppl 1):S29-31. No abstract available.

PMID:
17059911

Supplemental Content

Support Center